Peptides as Antibiotics: New Designs and Delivery Methods to Fight Drug-Resistant Bacteria

Two major peptide-based antimicrobial strategies are emerging. First, novel modified antimicrobial peptides (AMPs) are being engineered to overcome traditional AMP limitations like instability and toxicity while maintaining antibacterial activity. Second, cell-penetrating peptides (CPPs) conjugated to phosphorodiamidate morpholino oligomers (PPMOs) can deliver gene-specific antimicrobials directly into gram-negative bacteria. PPMOs maintain activity against multidrug-resistant strains and show effectiveness in biofilm settings — two critical advantages over conventional antibiotics. Resistance development to these peptide approaches appears slower than to traditional antibiotics.

The researchers conducted a review of current advances in two areas of peptide-based antibiotic research: direct-acting modified antimicrobial peptides and peptide-based delivery systems for antimicrobial compounds. They analyzed recent in vitro and in vivo data on peptide-conjugated PMOs (PPMOs), cell-penetrating peptide conjugates, and novel peptide designs.

Antibiotic resistance is one of the most urgent public health threats, and the pipeline of new traditional antibiotics is running dry. Peptide-based approaches represent entirely new mechanisms that bacteria haven't developed resistance to, potentially giving medicine new tools in the fight against superbugs and difficult-to-treat biofilm infections.

The antibiotic resistance crisis demands fundamentally new approaches, not just modifications of existing drug classes. Peptide-based antimicrobials — whether acting directly or serving as precision delivery vehicles — represent a paradigm shift in how we think about fighting infections. The ability of PPMOs to target specific bacterial genes while bypassing traditional resistance mechanisms could be transformative, especially for gram-negative superbugs that are most difficult to treat.

This is a review article without original experimental data. Many of the peptide antimicrobials discussed are still in preclinical development. Manufacturing costs remain high, and challenges around in vivo stability, potential toxicity, and pharmacokinetics have not been fully resolved. Clinical trial data for most approaches is limited or nonexistent.